CTx TFEBx
Alternative Names: CTx-TFEBxLatest Information Update: 20 Jan 2023
At a glance
- Originator Coave Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Neurodegenerative disorders
Most Recent Events
- 20 Jan 2023 Early research in Neurodegenerative disorders in France (Parenteral) (Coave Therapeutics pipeline, December 2022)
- 27 Dec 2022 Early research in Amyotrophic lateral sclerosis in France (Parenteral) (Coave Therapeutics pipeline, December 2022)